異位性皮膚炎，停用杜避炎後，能維持穩定膚況的患者不到百分之五（需搭配外用藥）- 日本研究
本篇研究 Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world，原文（外部網站）（Exp Dermatol. 2024 Sep;33(9):e15175. PMID: 39277874）。期刊摘要如下：
Possibility and appropriate timing of discontinuation of dupilumab for atopic dermatitis (AD) remain unclear. We explored the possibility of patients, who could maintain remission with topical therapy alone after withdrawing dupilumab in the real world. Furthermore, we identified their characteristics.
All adult AD patients who initiated dupilumab from June 2018 to July 2022 and were treated with dupilumab for more than 3 months at our hospital were included in this study. The observation period was from June 2018 to July 2023.
In 138 patients, 58 (42.0%) discontinued dupilumab at least once. Among them, 18 (13.0%) discontinued dupilumab but reinitiated dupilumab later due to exacerbation. Only seven patients (5.1%) could maintain remission with topical therapy alone after discontinuation of dupilumab, with characteristics of lower POEM, VAS of pruritus, serum levels of TARC and LDH, and neutrophil counts at baseline, and those of longer duration of dupilumab until its discontinuation (24.0 ± 13.3 vs. 12.8 ± 7.3 months) and lower EASI and affected BSA at the discontinuation of dupilumab.
In 118 patients treated with dupilumab for at least 1 year, 38 patients (32.2%) discontinued at least once. Only four patients (3.4%) could maintain remission with topical therapy alone after discontinuation of dupilumab, with characteristics of lower POEM at baseline and lower EASI at the discontinuation of dupilumab.
In conclusion, maintaining remission after withdrawing dupilumab is challenging. Discontinuation of dupilumab may be considered in patients with low baseline POEM, after more than 2 years of dupilumab treatment, with a substantial decrease in EASI.
原始論文
Watanabe A, Kamata M, Okada Y, Suzuki S, et al. Experimental Dermatology. 2024;33(9):e15175. doi:10.1111/exd.15175
論文摘要（Google 翻譯）
以下為 Google 翻譯，並校正明顯錯誤，僅供參考，內容以英文原文為準。
日本異位性皮膚炎患者停用 dupilumab 後僅以外用治療維持緩解的可能性，及其在真實世界中的特徵
異位性皮膚炎（AD）停用 dupilumab 的可能性與適當時機仍不清楚。我們在真實世界中探討患者停用 dupilumab 後，僅靠外用治療維持緩解的可能性，並進一步找出這些患者的特徵。
本研究納入 2018 年 6 月至 2022 年 7 月間在本院開始使用 dupilumab、且使用超過 3 個月的所有成年 AD 患者。觀察期間為 2018 年 6 月至 2023 年 7 月。
138 名患者中，58 名（42.0%）至少停用 dupilumab 一次。其中 18 名（13.0%）停用後因病情惡化而重新使用 dupilumab。僅有 7 名患者（5.1%）在停用 dupilumab 後能僅靠外用治療維持緩解，其特徵為基線時 POEM、搔癢 VAS、血清 TARC 與 LDH 濃度及嗜中性白血球數較低，停藥前使用 dupilumab 的時間較長（24.0 ± 13.3 對 12.8 ± 7.3 個月），且停藥時 EASI 與受侵犯體表面積（BSA）較低。
在使用 dupilumab 至少 1 年的 118 名患者中，38 名（32.2%）至少停藥一次。僅有 4 名患者（3.4%）在停用 dupilumab 後能僅靠外用治療維持緩解，其特徵為基線 POEM 較低，且停藥時 EASI 較低。
總之，停用 dupilumab 後要維持緩解並不容易。對於基線 POEM 低、使用 dupilumab 超過 2 年且 EASI 大幅下降的患者，可考慮停用 dupilumab。
原部落格的分類彙整：
原文發表於 作者部落格（舊部落格）。